Novo Nordisk CEO: Strategy remains constant after Krogsgaard's departure
Novo Nordisk maintains its strategy even though EVP, R&D Head and CSO Mads Krogsgaard Thomsen leaves the firm at the end of the month, according to CEO Lars Fruergaard Jørgensen.
BY RITZAU FINANS & CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN
After 20 years in the driver's seat, Mads Krogsgaard Thomsen passes the baton of his Novo Nordisk research and development responsibility areas to two of his lieutenants. The transition will be smooth, since the unit will keep going along the same strategic lines, says Novo Nordisk CEO and President Lars Fruergaard Jørgensen on Wednesday at an investor teleconference in connection with the release of the company's annual report for 2020.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Novo Nordisk expects 5-9 percent sales growth in 2021
For subscribers
Mads Krogsgaard Thomsen resigns from Novo Nordisk
For subscribers
